Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
About this study
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
- Condition
- Prostate Cancer
- Tested
- PSMA-PET CT
- Sponsor
- Weill Medical College of Cornell University
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 10
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Prostate Cancer
- Males aged ≥ 18.
- Histologically confirmed low or favorable intermediate risk prostate cancer per NCCN guidelines. (Note: Grade Group 2 must have 20% or less involvement in every core and no presence of cribiform or intraductal carcinoma).
- PSA \< 20 ng/ml.
- Ability to undergo yearly PSMA-PET CT.
- Ability to undergo yearly prostate mpMRI.
- Ability to undergo transrectal or transperineal template and fusion prostate biopsy.
- Willingness to undergo yearly prostate biopsies.
Exclusion 6
- History of prior treatment for prostate cancer.
- History of systemic therapy for prostate cancer.
- Inability to undergo transrectal ultrasound.
- Life expectancy less than 10 years.
- Not interested in pursuing active surveillance.
- Initial diagnosis of prostate cancer greater than 15 months.
Where
4 sites, 4 recruiting
UH Cleveland Medical Center
Cleveland, Ohio, United States
Weill Cornell Medicine - New York Presbyterian Hospital
New York, New York, United States
UCLA
Los Angeles, California, United States
UCSF
San Francisco, California, United States
Contact
-
Holly Kuczynski
646-962-7523 hok4001@med.cornell.edu
-
Sarah Yuan
646-962-6040 say7008@med.cornell.edu
Potential match only. Final eligibility is determined by the study team.